Teleflex reports four-year BIOMAG-I data supporting Freesolve resorbable magnesium scaffold safety

Teleflex Incorporated

Teleflex Incorporated

TFX

0.00
  • Teleflex disclosed four-year follow-up results from the BIOMAG-I first-in-human study, already presented at the EuroPCR conference in Paris.
  • The data showed a favorable long-term safety profile for its Freesolve resorbable magnesium coronary scaffold, with no new cardiac-related events in later follow-up.
  • Results supported sustained device performance, reinforcing the “leave nothing behind” strategy versus permanent implants.
  • The readout underpins ongoing BIOMAG-II work, with a BIOMAG-III randomized trial planned to position the scaffold against drug-eluting stents.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260609079857) on June 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.